Latest Stories for GlycoMimetics, Inc.

2015-04-07T04:00:52-07:00

– GlycoMimetics to receive $20 million milestone payment upon dosing of first patient in trial – ]]>

2015-03-19T06:30:16-07:00

]]>

2015-03-16T13:30:34-07:00

Year-End Cash and Cash Equivalents of $55.2 million ]]>

2015-03-03T06:06:10-08:00

- Data underscores potential to provide meaningful clinical benefits and pharmacoeconomic impacts for patients in vaso-occlusive crisis - ]]>

2015-02-26T06:04:47-08:00

]]>

2015-02-03T06:05:48-08:00

]]>

2014-12-09T06:09:01-08:00

Preclinical Data Shared Through Four Oral Presentations and One Poster Focus on the Potential Role of GMI-1271 in Treating Blood Cancers and Coagulation Disorders Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via Poster Session at ASH Meeting ]]>

2014-12-04T06:04:07-08:00

- National Heart Lung and Blood Institute grant is funding University of Michigan Phase 1 trial ]]>

2014-11-17T13:00:13-08:00

- E-selectin antagonist GMI-1271 to advance to chemo-combination study in AML - ]]>

2014-11-12T06:06:37-08:00

]]>

2014-11-06T06:33:13-08:00

Preclinical data on GMI-1271 in four oral presentations and one poster focus on blood cancers and coagulation disorders New data for rivipansel, sickle cell investigational drug candidate, show effects on biomarkers ]]>

2014-10-31T06:15:07-07:00

]]>

2014-08-08T07:39:10-07:00

]]>

2014-07-31T13:00:38-07:00

]]>

2014-07-10T06:08:46-07:00

- Dr. Goldberg Brings Perspective as Medical Oncologist and Hematologist and Extensive Biopharmaceutical Regulatory Experience to GlycoMimetics Board - ]]>